Details for Patent: 8,536,206

Which drugs does patent 8,536,206 protect, and when does it expire?

Patent 8,536,206 protects DALIRESP and is included in one NDA.

This patent has thirty-seven patent family members in twenty-nine countries.

Summary for Patent: 8,536,206

Title:	Process for the preparation of roflumilast
Abstract:	The invention relates to novel processes for the preparation of high-purity roflumilast.
Inventor(s):	Kohl; Bernhard (Constance, DE), Mueller; Bernd (Constance, DE), Palosch; Walter (Rielasingen, DE)
Assignee:	Takeda GmbH (Konstanz, DE)
Application Number:	13/547,945
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,536,206
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form; Formulation;

Drugs Protected by US Patent 8,536,206

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	DALIRESP	roflumilast	TABLET;ORAL	022522-002	Jan 23, 2018	AB	RX	Yes	No						TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
Astrazeneca	DALIRESP	roflumilast	TABLET;ORAL	022522-001	Feb 28, 2011	AB	RX	Yes	Yes						TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

Foreign Priority and PCT Information for Patent: 8,536,206

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	03005245	Mar 08, 2003

International Family Members for US Patent 8,536,206

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	043531
Austria	447555
Australia	2004220357
Brazil	PI0406427
Canada	2503290